ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Historical Holders from Q4 2020 to Q3 2025

Symbol
SPRY on Nasdaq
CUSIP
82835W108
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
98.6M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
84.5M
Holdings value
$1.48B
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
185
Number of buys
107
Number of sells
-69
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 11.1% $111M 10.9M RA Capital Management, L.P. Sep 29, 2025
Flynn James E 7.75% -11.6% $101M -$13.6M 7.61M -11.9% Deerfield Management Company, L.P. Jul 30, 2025

Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 319K $3.2M -$902K $10.05 10
2025 Q2 84.5M $1.48B +$150M $17.45 185
2025 Q1 76.2M $959M +$63.8M $12.58 182
2024 Q4 71.3M $752M +$68.7M $10.55 162
2024 Q3 63.8M $926M +$31M $14.50 150
2024 Q2 62.6M $532M +$21.9M $8.51 112
2024 Q1 59.9M $612M -$15.9M $10.22 114
2023 Q4 65.4M $358M -$3M $5.48 98
2023 Q3 66.5M $251M +$40.3M $3.78 95
2023 Q2 54.8M $367M +$9.83M $6.70 92
2023 Q1 53.4M $348M +$19.4M $6.51 88
2022 Q4 50.2M $428M +$173M $8.53 72
2022 Q3 30.4M $160M +$25M $5.28 57
2022 Q2 26.1M $111M -$872K $4.24 60
2022 Q1 27M $94.7M -$19.3M $3.51 65
2021 Q4 30.1M $200M -$13.2M $6.66 72
2021 Q3 28.9M $288M -$42.5M $9.98 74
2021 Q2 28M $865M -$827K $30.89 74
2021 Q1 27.7M $1.21B +$139M $43.63 66
2020 Q4 24.4M $1.13B +$1.12B $46.34 60